Bintrafusp alfa
Bintrafusp alfa is a protein pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against programmed cell death 1 ligand 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 10 | 8 | 1 | — | 1 | 15 |
| Lung neoplasms | D008175 | — | C34.90 | 4 | 8 | 2 | — | — | 10 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 7 | 1 | — | — | 8 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 3 | 1 | — | — | 4 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 3 | 1 | — | — | 3 |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | — | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 2 | 6 | — | — | 1 | 7 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 2 | — | — | — | 7 |
| Uterine cervical neoplasms | D002583 | — | — | 4 | 5 | — | — | — | 6 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | 2 | — | — | — | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 4 | 4 | — | — | — | 4 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 3 | 4 | — | — | — | 4 |
| Oropharyngeal neoplasms | D009959 | — | — | 3 | 4 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 2 | 4 | — | — | — | 4 |
| Squamous cell carcinoma | D002294 | — | — | 2 | 3 | — | — | 1 | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 4 | — | — | — | 4 |
Show 38 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | — | — | — | 1 | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bintrafusp alfa |
| INN | bintrafusp alfa |
| Description | Bintrafusp alfa is a protein pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against programmed cell death 1 ligand 1. |
| Classification | Protein |
| Drug class | fusion proteins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298024 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | NW9K8C1JN3 (ChemIDplus, GSRS) |
Target
Agency Approved
CD274
CD274
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,174 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use